Arcturus Therapeutics Holdings (ARCT) Asset Utilization Ratio (2019 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported Asset Utilization Ratio of 0.21 for Q1 2026, down 50.18% on a YoY basis from 0.43 in Q1 2025, and down 28.54% quarter-over-quarter from 0.3 in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.21 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio fell 50.18% year-over-year to 0.21; the trailing twelve-month figure through Mar 2026 stood at 0.21 (down 50.18% YoY), and the FY2025 full-year result was 0.27, down 32.29% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.21, down from 0.3 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.67 in Q3 2023, with the low at 0.04 in Q1 2022.
- Historically, Asset Utilization Ratio has averaged 0.37 across 5 years, with a median of 0.38 in 2025.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 1753.49% — and 2024, when it sank 51.88%.
- Arcturus Therapeutics Holdings' Asset Utilization Ratio stood at 0.55 in 2022, then tumbled by 32.09% to 0.38 in 2023, then gained by 13.33% to 0.43 in 2024, then slumped by 30.45% to 0.3 in 2025, then slipped by 28.54% to 0.21 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.21 (Q1 2026), 0.3 (Q4 2025), and 0.33 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | 0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.21 |
| Dec 31, 2025 | 0.30 |
| Sep 30, 2025 | 0.33 |
| Jun 30, 2025 | 0.38 |
| Mar 31, 2025 | 0.43 |
| Dec 31, 2024 | 0.43 |
| Sep 30, 2024 | 0.42 |
| Jun 30, 2024 | 0.41 |
| Mar 31, 2024 | 0.29 |
| Dec 31, 2023 | 0.38 |
| Sep 30, 2023 | 0.67 |
| Jun 30, 2023 | 0.59 |
| Mar 31, 2023 | 0.61 |
| Dec 31, 2022 | 0.55 |
| Sep 30, 2022 | 0.16 |
| Jun 30, 2022 | 0.12 |
| Mar 31, 2022 | 0.04 |
| Dec 31, 2021 | 0.03 |
| Sep 30, 2021 | 0.02 |
| Jun 30, 2021 | 0.02 |